Neurodegenerative disorders leading to dementia are common diseases that affect many older and some young adults. Neuroimaging methods are important tools for assessing and monitoring pathological brain changes associated with progressive neurodegenerative conditions. In this review, the authors describe key findings from neuroimaging studies (magnetic resonance imaging and radionucleotide imaging) in neurodegenerative disorders, including Alzheimer’s disease (AD) and prodromal stages, familial and atypical AD syndromes, frontotemporal dementia, amyotrophic lateral sclerosis with and without dementia, Parkinson’s disease with and without dementia, dementia with Lewy bodies, Huntington’s disease, multiple sclerosis, HIV-associated neurocognitive disorder, and prion protein associated diseases (i.e., Creutzfeldt-Jakob disease). The authors focus on neuroimaging findings of in vivo pathology in these disorders, as well as the potential for neuroimaging to provide useful information for differential diagnosis of neurodegenerative disorders.
can affect younger individuals. With disparate, but sometimes overlapping clinical presentations and etiologies, neurodegenerative disorders and dementias can be difficult to correctly diagnose. Neuroimaging techniques have the potential to assist with clinical diagnosis and monitoring of disease progression in most, if not all, of the neurodegenerative disorders. Our goal here is to provide an overview of neuroimaging findings in the most common neurodegenerative conditions, as well as recent developments in each area (Table 1).

### Degenerative Diseases and Dementias

Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease, affecting more than 5 million individuals in the United States, mostly age 65 or older, and that number is expected to more than triple by 2050. The earliest clinical symptoms are memory impairments, particularly in episodic and semantic domains, as well as deficits in language and executive functioning. Patients with AD also show a significant impairment in daily functioning with disruption or cessation of the ability to perform complex activities and later more simple tasks. Clinicians and researchers have recently updated AD diagnostic criteria for use in clinical practice and research. Currently, the diagnosis of AD is made clinically, based on cognition and the relative impact of impairments on daily activities. Attempts to diagnose AD at an earlier stage have led to the development of a clinical syndrome termed amnestic mild cognitive impairment (MCI). Recently, new criteria for diagnosis of MCI in clinical and research settings have been published. Patients with MCI typically show deficits in episodic memory that fall more than 1 standard deviation below age and education adjusted and culturally appropriate normative levels. More recently, researchers have proposed dividing MCI into an earlier stage (early MCI [E-MCI]) and a later stage (late MCI [L-MCI]), with E-MCI patients showing a 1 to 1.5 standard deviation memory deficit and L-MCI showing a greater than 1.5 standard deviation deficit. This classification has only recently been introduced and future studies will help to elucidate differences between these MCI subgroups. The most common presentation of MCI features memory impairment (amnestic MCI), but can co-occur with other cognitive deficits such as executive function or language deficits (multidomain MCI). Amnestic MCI is widely considered to be a prodromal form of AD, as nearly 10 to 15% of amnestic L-MCI patients convert to probable AD each year, relative to only 1 to 2% of the general older adult population. Recently, researchers and clinicians have been attempting to detect AD-related changes and predict progression even earlier than MCI (e.g., pre-MCI or preclinical AD). A conceptual framework for identifying preclinical AD patients has been presented in a recent article.

Alzheimer’s disease is characterized by two neuropathological hallmarks: amyloid plaques and neurofibrillary tangles. Amyloid plaques are extracellular aggregations of the amyloid-β (Aβ) peptide that are found throughout the brain of AD patients. Neurofibrillary tangles result from the hyperphosphorylation of the microtubule-associated protein tau, which forms insoluble filamentous structures that combine to create paired helical filaments, a key component of the neurofibrillary tangles seen in the brains of patients with AD. The temporal relationship and direct link between amyloid plaques and neurofibrillary tangles is not completely elucidated at this time. Current theories suggest that amyloid plaque formation precedes neurofibrillary tangles, with amyloid accumulation occurring during a long preclinical period lasting years to decades. The biochemical processes involved in Alzheimer’s disease development ultimately converge upon widespread cell death and neuronal loss, likely through apoptosis. The first regions of the brain to show neuronal loss associated with AD are in the medial temporal lobe (MTL), including the entorhinal cortex, hippocampus, amygdala, and parahippocampal cortex, as well as cholinergic innervations to the neocortex from the nucleus basalis of Meynert. By the time a patient has reached a diagnosis of AD, neurodegeneration is usually found throughout the neocortex and subcortical regions, with significant atrophy of the temporal, parietal, and frontal cortices, but relative sparing of the primary occipital cortex and primary sensory–motor regions.

Although the majority of AD cases represent late-onset or sporadic AD, nearly 5% of AD cases are caused by dominantly inherited genetic mutations, usually in one of three genes: amyloid precursor protein (APP), presenilin 1 (PS1), or presenilin 2 (PS2). Often featuring an onset of symptoms that is at an earlier age than sporadic AD patients (i.e., before age 65), these cases are referred to as familial AD or early-onset AD. Although these diseases can show somewhat different symptomology and pathology than late-onset AD, the major AD hallmarks (i.e., amyloid plaques, neurofibrillary tangles) are present. Therefore, these patients may represent a useful sample for studying early changes in biomarkers, particularly because the age of symptom onset tends to be consistent across generations. Therefore, using an estimated age of symptom onset (EAO), changes in neuropathology and cognition can be assessed using biomarkers decades before onset of disease. Other diseases associated with AD neuropathology show atypical presentation, including posterior cortical atrophy (PCA) and logopenic aphasia. Posterior cortical atrophy is a disorder of higher visual function that causes significant visual dysfunction in the absence of ocular disease, as well as constructional apraxia, visual field deficits, and environmental disorientation. This disorder is primarily thought to be associated with changes in posterior brain regions, including the parietal and occipital lobes. Logopenic aphasia is a type of primary progressive aphasia (PPA) associated with AD (i.e., amyloid) rather than frontotemporal dementia- (FTD-) like pathology and features impaired word retrieval and sentence repetition in the absence of motor speech or grammatical abnormalities. Cerebral amyloid angiopathy (CAA) is also associated with AD-like amyloid pathology. However, amyloid deposits are largely observed in the walls of small cerebral arteries and capillaries in CAA. Patients with CAA often show cognitive decline, seizures, headaches, and stroke-like symptoms.

Vascular dementia and vascular-associated cognitive impairment (VCI), a form of cognitive impairment with notable
<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical symptoms</th>
<th>Atrophy pattern</th>
<th>Functional activation/ connectivity changes</th>
<th>Molecular changes</th>
<th>Other imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sporadic Alzheimer’s disease (AD)</td>
<td>Memory decline; Impairment in other cognitive domains; Dementia; Functional decline</td>
<td>MCI/mild AD: Atrophy of MTL (Hipp, EC), lateral temporal lobe, &amp; parietal lobes</td>
<td>↓ or ↓ activation of task-related regions during cognitive tasks ↓ connectivity of brain networks (e.g., DMN)</td>
<td>[18F]FDG: ↓ metabolism in temporo-parietal regions Amyloid PET positive ↓ ACh, GABA, 5-HT, &amp; DA neurotransmission ↓ activated microglia</td>
<td>MRS: ↓ NAA, ↓ mins DTI: Widespread atrophy of frontal, temporal, &amp; parietal white matter tracts ASL/SPECT: ↓ perfusion of temporoparietal regions</td>
</tr>
<tr>
<td>Familial AD</td>
<td>Decline in memory and other cognitive domains; Dementia; Functional decline</td>
<td>Atrophy in the MTL (Hipp, EC), lateral temporal lobe, &amp; parietal cortex</td>
<td>↓ or ↓ activation of task-related regions during cognitive tasks ↓ and ↓ connectivity of DMN network</td>
<td>[18F]FDG: ↓ metabolism in temporo-parietal regions Amyloid PET positive ↓ sporadic AD-like pattern plus striatal binding</td>
<td>DTI: Reduced integrity of fornix, EC, cingulum, and subcortical white matter tracts SPECT: ↓ perfusion of temporoparietal regions</td>
</tr>
<tr>
<td>Posterior cortical atrophy</td>
<td>Visual and visuospatial deficits</td>
<td>Atrophy of posterior brain regions (posterior temporal, parietal, occipital lobes)</td>
<td>n/a</td>
<td>Amyloid PET positive</td>
<td>DTI: ↓ white matter integrity in ventral visual processing stream ASL/SPECT: ↓ perfusion in occipito-parietal lobe, ↓ in frontal lobe, anterior cingulate, mesiotemporal lobe</td>
</tr>
<tr>
<td>Logogenic aphasia</td>
<td>Impaired language (word retrieval, sentence repetition)</td>
<td>Atrophy of posterior temporal lobe, temporo-parietal lobe, medial parietal lobe, MTL (left &gt; right)</td>
<td>n/a</td>
<td>[18F]FDG: ↓ metabolism left temporo-parietal lobe Amyloid PET positive</td>
<td>DTI: ↓ white matter integrity in left temporo-parietal region ASL/SPECT: ↓ perfusion in left temporo-parietal lobe</td>
</tr>
<tr>
<td>Cerebral amyloid angiopathy</td>
<td>Cognitive/ functional decline in any domain</td>
<td>Generalized cerebral atrophy with cerebral microhemorrhages, microbleeds, and other ischemic-related changes</td>
<td>Altered vascular reactivity during visual stimulation</td>
<td>Amyloid PET positive</td>
<td>SPECT: ↓ perfusion in parietal, temporal, and frontal lobes</td>
</tr>
<tr>
<td>Vascular dementia</td>
<td>Significant cognitive decline in any domain coupled with vascular event</td>
<td>Atrophy of the cerebral cortex and MTL; ischemic-related changes (i.e., white matter lesions)</td>
<td>↓ Activation and altered blood flow-metabolic coupling during cognitive and motor tasks ↓ Connectivity in the posterior cingulate</td>
<td>[18F]FDG: ↓ metabolism in frontotemporal and parietal lobes Amyloid PET negative</td>
<td>DTI: ↓ white matter integrity in widespread cortical regions (even in normal appearing white matter) ASL/SPECT: ↓ perfusion in frontal and parietal lobes</td>
</tr>
<tr>
<td>Behavioral variant FTD</td>
<td>Personality and behavior changes (disinhibition, apathy, loss of empathy, etc.)</td>
<td>Atrophy in the frontal lobe, anterior cingulate, anterior insula, thalamus</td>
<td>↓ Activation in frontal and parietal lobe during working memory; altered activation during emotional tasks ↓ Connectivity in basal ganglia, frontal lobe (i.e., salience network)</td>
<td>[18F]FDG: ↓ Metabolism frontal lobe Amyloid PET negative</td>
<td>DTI: ↓ white matter integrity in frontal and temporal lobes ASL/SPECT: ↓ perfusion in frontal and parietal lobes</td>
</tr>
<tr>
<td>Semantic dementia</td>
<td>Impaired language/ fluency (fluent aphasia, anomia, etc.)</td>
<td>Asymmetrical atrophy of the anterior, medial, &amp; inferior temporal lobes (left &gt; right)</td>
<td>Altered activation during sound, memory, &amp; language tasks ↓ connectivity in frontotemporal and frontolimbic networks; ↓ connectivity in PFC</td>
<td>[18F]FDG: ↓ Metabolism in the left anterior temporal lobe Amyloid PET negative</td>
<td>DTI: ↓ white matter integrity in bilateral (left &gt; right) temporal lobes ASL/SPECT: ↓ perfusion in the left anterior temporal lobe</td>
</tr>
<tr>
<td>Progressive nonfluent aphasia (PNFA)</td>
<td>Impaired language (difficulty in speech production).</td>
<td>Mild PNFA: Atrophy in left inferior frontal, insula, premotor cortex, temporal lobe</td>
<td>↓ Activation during sentence reading and comprehension</td>
<td>[18F]FDG: ↓ metabolism in the frontal lobe, insula, motor areas</td>
<td>DTI: ↓ white matter integrity in frontal lobe, insula, &amp; superior motor pathway</td>
</tr>
</tbody>
</table>

Table 1: Brief Summary of Neuroimaging Findings in Selected Neurodegenerative Diseases and Dementias
<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical symptoms</th>
<th>Atrophy pattern</th>
<th>Functional activation/ connectivity changes</th>
<th>Molecular changes</th>
<th>Other imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>FTD with motor neuron disease (FTD-MND/ FTD-ALS)</td>
<td>Behavioral/language impairments with motor dysfunction</td>
<td>Atrophy of frontal and temporal lobes, anterior cingulate, occipital lobe, precentral gyrus</td>
<td>↓ Activation in frontal lobe, anterior cingulate, temporal lobe, occipitotemporal lobe during verbal fluency and emotional task</td>
<td>Amyloid PET negative (except those with Pick’s disease) Reduced striatal DA</td>
<td>ASL/SPECT: ↓ perfusion in the left anterior temporal lobe</td>
</tr>
<tr>
<td>Amyotrophic lateral sclerosis</td>
<td>Motor dysfunction</td>
<td>Atrophy of motor and extramotor regions (i.e., precentral gyrus)</td>
<td>↑ or ↓ activation of task-related regions during motor &amp; emotional tasks</td>
<td>[18F]FDG: ↓ metabolism in the frontal and temporal lobes, basal ganglia, thalamus Reduced frontal lobe 5-HT binding Reduced GABA-A receptors in cerebral cortex and insula</td>
<td>DTI: ↓ white matter integrity in CC, CST, cingulum, frontal &amp; temporal white matter tracts ASL/SPECT: ↓ perfusion frontal and temporal lobes</td>
</tr>
<tr>
<td>Parkinson’s disease dementia (PDD)/ dementia with Lewy bodies (DLB)</td>
<td>Motor dysfunction with cognitive impairment (spontaneous motor Parkinsonism, visual hallucinations, etc.)</td>
<td>Widespread cortical and subcortical atrophy</td>
<td>↑ or ↓ activation during visual tasks</td>
<td>[18F]FDG: ↓ metabolism in the basal ganglia, cerebellum, and cerebral cortex Some amyloid PET positive ↓ striatal DA &amp; cortical ACh neurotransmission</td>
<td>MRS: ↓ NAA, ↓ mIns, choline, GlmN, GmN, DTI: ↓ white matter integrity in CC, CST, PDD, cingulum, frontal &amp; temporal white matter tracts ASL/SPECT: ↓ perfusion in posterior cortex</td>
</tr>
<tr>
<td>Parkinson’s disease (no dementia)</td>
<td>Motor dysfunction (spontaneous motor Parkinsonism, visual hallucinations, etc.)</td>
<td>Less atrophy than in PDD/DLB but with a similar anatomic distribution</td>
<td>Similar but less severe functional and connectivity changes to those seen in PDD/DLB</td>
<td>[18F]FDG: ↓ metabolism in the basal ganglia, thalamus, and cerebral cortex ↓ DA, 5-HT, ACh, GABA, opioid neurotransmission ↓ activated microglia in striatal and extrastriatal regions</td>
<td>Similar but less severe changes on MRS, DTI, and ASL/SPECT to those seen in PDD/DLB</td>
</tr>
<tr>
<td>Huntington’s disease</td>
<td>Motor dysfunction with cognitive impairment (bradykinesia, incoordination, etc.); linked to mutation in HTT gene</td>
<td>Atrophy of striatum, cerebral cortex, cingulate, thalamus, and white matter regions</td>
<td>↑ or ↓ activation during motor &amp; cognitive tasks</td>
<td>[18F]FDG: ↓ cortical metabolism ↓ DA receptors activated microglia in striatum, extra-striatal regions, hypothalamus</td>
<td>DTI: ↓ integrity in frontal lobe, sensorimotor cortex, CC, internal capsule, and basal ganglia</td>
</tr>
<tr>
<td>Multiple sclerosis (MS)</td>
<td>Heterogeneous symptoms (autonomic, visual, motor, &amp;/or sensory dysfunction)</td>
<td>Focal hyperintense lesions in white matter on T2-weighted scans; cerebral and cerebellar atrophy</td>
<td>↑ or ↓ activation during memory, attention, and executive tasks</td>
<td>[18F]FDG: ↓ metabolism in thalamus, deep gray matter structures, &amp; frontal lobe ↓ activated microglia in normal and lesioned gray matter and white matter</td>
<td>DTI: ↓ integrity of normal and lesioned white matter and gray matter ASL/SPECT: ↓ cerebral perfusion</td>
</tr>
<tr>
<td>HIV-Associated neurocognitive disorder</td>
<td>Impairment in executive function, motor speed, attention/working memory and episodic memory</td>
<td>Gray matter atrophy in anterior cingulate, lateral temporal lobe, and cerebral cortex; Cortical thinning in primary motor and</td>
<td>↑ or ↓ activation during memory, attention, executive function, and motor tasks</td>
<td>[18F]FDG: ↓ cortical metabolism but ↑ metabolism in the basal ganglia</td>
<td>MRS: ↓ NAA, ↓ mIns, choline, GlmN/Cr, mIns/Cr in frontal gray matter, white matter, and basal ganglia DTI: ↓ integrity in cortical eloquence</td>
</tr>
</tbody>
</table>
cerebrovascular pathology and/or risk factors, can be identified using self-reports of stroke and/or other vascular events or diseases (myocardial infarction, atherosclerosis, hypertension, etc.), neurologic and psychometric evaluation, and/or structural and functional imaging techniques. The major requirements for a diagnosis of vascular dementia or vascular-associated MCI include the presence of clinically significant cognitive impairments, which can be in any cognitive domain, but are commonly observed in executive function and/or memory, and the presence of significant cerebrovascular pathology and/or risk factors, assessed using clinical or neuroimaging techniques. Beyond these requirements, patients are diagnosed by clinical severity and the impact on activities of daily living (ADLs), similar to the diagnosis of AD. Specifically, patients diagnosed with vascular-associated MCI must show a cognitive deficit, but no significant impairment in ADLs, whereas a diagnosis of vascular dementia requires significant impairment in both clinically assessed cognitive status and ADLs.

Frontotemporal dementia (FTD) is an overarching diagnosis that encompasses multiple disorders with varying symptoms. Behavioral variant FTD (bvFTD) is characterized by a change in personality and behavior, disinhibition, apathy, loss of empathy, obsessive–compulsive behaviors, and changes in appetite.13,16,17 Behavioral variant FTD is most commonly associated with pathological tau accumulation, such as seen in Pick's disease, but can also feature accumulation of a TAR-DNA-binding protein called TDP-43.13,17 Primary progressive aphasia (PPA) is another form of FTD, which is divided into two forms: semantic dementia (SD) and progressive nonfluent aphasia (PNFA). Semantic dementia features fluent aphasia, anomia, and single-word comprehension deficits and later in the disease course behavioral symptoms similar to those seen bvFTD. Pathologically, TDP-43 accumulation usually underlies SD, but rare cases featuring tau pathology associated with Pick's disease have been observed.13,17 Progressive nonfluent aphasia features speech production difficulties with agrammatism and apraxia of speech, as well as phonemic errors, anomia, and impairments in sentence comprehension.13 Progressive nonfluent aphasia typically features changes due to tau pathology, although mutations in the progranulin gene (GRN) resulting in TDP-43 pathology, can cause PNFA symptoms, but without apraxia of speech.13,17 Frontotemporal dementia can also feature motor dysfunction and motor neuron disease (MND).13,17,18 These disorders have been linked to Parkinson's-like symptoms, such as those seen in corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), which feature tau pathology, or changes due to TDP-43 pathology, which presents as FTD-MND with Lewy body-like pathology or FTD associated with amyotrophic lateral sclerosis (FTD-ALS).14,17,18 Clinically, the Parkinson's-like FTD dementias (CBD and PSP) can show either behavioral-type symptoms (i.e., those seen in bvFTD) or language-type symptoms (most commonly PFNA-like symptoms), along with executive dysfunction, in the presence of cortical and extrapyramidal motor dysfunction.13 Patients with FTD associated with TDP-43 (FTD-ALS, others) most commonly present with behavioral symptoms (bvFTD-like) in the presence of motor dysfunction.18 Amyotrophic lateral sclerosis can also occur without behavioral symptoms, although non-FTD ALS patients commonly still have subthreshold cognitive changes.19

Parkinson's disease (PD) is caused by deposition of inclusions of α-synuclein called Lewy bodies and feature spontaneous motor Parkinsonism, visual hallucinations, and potentially changes in cognition20; 70 to 80% of patients with PD develop cognitive impairment and/or dementia over the course of the disease.20,21 Two types of Parkinson's

---

**Table 1 (Continued)**

<table>
<thead>
<tr>
<th>Disease</th>
<th>Clinical symptoms</th>
<th>Atrophy pattern</th>
<th>Functional activation/connectivity changes</th>
<th>Molecular changes</th>
<th>Other imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sporadic/variant CJD; genetic CJD/GSS/FFI</td>
<td>Motor dysfunction, cognitive impairment, and psychiatric symptoms; FFI also features insomnia</td>
<td>Abnormalities of the basal ganglia, thalamus cerebellum, cortical gray matter &amp; white matter</td>
<td></td>
<td>n/a</td>
<td>[18F]FDG: ↓ cortical metabolism</td>
</tr>
</tbody>
</table>

Abbreviations: 5-HT, serotonin; ACh, acetylcholine; ASL, arterial spin labeling; CC, corpus callosum; CJD, Creutzfeld-Jakob disease; Cr, creatinine; CST, corticospinal tract; DA, dopamine; DMN, default-mode network; DTI, diffusion tensor imaging; EC, entorhinal cortex; FDG, [18F]fluorodeoxyglucose; FFI, familial fatal insomnia; FTD, frontotemporal dementia; Glrm, glutamine; Glmt, glutamate; GSS, Gerstmann-Sträussler-Scheinker disease; Hipp, hippocampus; MCI, mild cognitive impairment; mLns, myo-inositol; MRS, magnetic resonance spectroscopy; MTL, medial temporal lobe; NAA, N-acetylaspartate; PET, positron emission tomography; PLIC, posterior limb of the internal capsule; SPECT, single-photon emission computed tomography.
dementias have been defined, including Parkinson’s disease dementia (PDD), in which patients develop cognitive symptoms more than 1 year after motor symptoms, and dementia with Lewy bodies (DLB), in which patients develop cognitive symptoms concurrent with or within a year of motor symptoms.20 Cognitive symptoms in PDD and DLB are variable, but often feature impairments in visual spatial functioning, executive function, language, and/or memory.20,21 However, whether PDD and DLB actually represent separate disorders is under debate.20 Thus, in the present article, PDD and DLB will be discussed together.

Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative condition caused by the trinucleotide repeats (CAG) in the gene coding for the protein huntingtin (HTT). Pathological features include progressive degeneration of striatal GABAergic interneurons.2,22 Clinical symptoms of HD include motor symptoms, such as chorea, bradykinesia, dystonia, and incoordination, and cognitive symptoms, including changes in visuomotor function, executive function, and memory.22 Because HD is an autosomal dominant disorder, prodromal phases of this disease can be studied (i.e., prior to clinical onset in mutation carriers) to assess disease development and progression.

Multiple sclerosis (MS) is a neurodegenerative condition featuring degeneration of the myelin sheaths that surround neuronal axons, which results in significant impairment in neuronal transmission.23,24 Although the exact cause of MS is unknown, it is thought to be the result of either an autoimmune syndrome in which inflammatory cells attack the myelin or a dysfunction of the myelin-producing cells.25 Multiple sclerosis typically presents either as discrete attacks (relapsing-remitting) or progressive over time (progressive MS).26 Symptoms of MS can vary dramatically, as MS lesions can occur throughout the cortical white matter, but the most common are autonomic, visual, motor, and sensory problems.24 Cognitive symptoms usually include behavioral and emotional changes (i.e., depression), as well as impairments in executive functioning, attention, and memory.24

HIV-associated neurocognitive disorders (HAND) can be classified into three types based on severity: (1) asymptomatic neurocognitive impairment (ANI), which features cognitive impairment 1 SD below age and education adjusted norms in two cognitive domains but no functional impairment; (2) HIV-associated mild neocognitive disorder (HMD; also referred to as mild cognitive motor dysfunction [MCMD]), which features cognitive impairment 1 SD below adjusted norms in two cognitive domains and mild impairment in daily functioning; (3) HIV-associated dementia (HAD; also known as AIDS dementia complex [ADC]), which is characterized by cognitive impairment 2 SD or more below age- and education-adjusted norms in at least two cognitive domains and significant impairment in daily functioning.27 In the present review, we will combine these three severity categories into one group (HAND). Although these classifications may represent stages of disease, further study is needed for this determination. Approximately 22 to 55% of patients with acquired immunodeficiency syndrome (AIDS) show cognitive dysfunction. Symptoms include disorientation, mood disturbances, and impairment in executive function, speed of information processing, attention and working memory, motor speed, and new learning and retrieval.28–31 However, long-term and semantic memory, language, and visuospatial function remain relatively intact.31 Some patients also show motor symptoms.29 However, symptoms can vary significantly across individuals.31

Prion-associated diseases are rare neurodegenerative disorders caused by abnormal processing of the prion protein, which leads to lethal transmissible spongiform encephalopathies (TSEs).1 Prion-associated diseases can either be sporadic (sporadic Creutzfeldt-Jakob disease [sCJD]; sporadic fatal insomnia [SFI]), genetic (genetic CJD; Gerstmann-Strassler-Scheinker diseases [GSS]; fatal familial insomnia [FFI]), or acquired through infectious transmission of tissue carrying the misfolded prion protein (Kuru; iatrogenic CJD [iCJD]; variant CJD [vCJD]).1 The different variants of prion-associated dementia show somewhat different symptoms, including varying rates of progression and ages of onset, but the majority feature significant motor and sensory dysfunction, cognitive impairment, and personality changes or psychiatric disorders.3

**Neuroimaging Biomarkers**

The two types of neuroimaging most commonly used as biomarkers of neurodegeneration and dementia include magnetic resonance imaging (MRI) and radionucleotide imaging (i.e., single-photon emission computerized tomography [SPECT], positron emission tomography [PET]). The most widely used neuroimaging technique to investigate anatomical changes and neurodegeneration in vivo is structural MRI, which can assess global and local atrophic brain changes. More advanced structural MRI techniques, including diffusion weighted and diffusion tensor imaging [DWI/DTI], magnetic resonance spectroscopy [MRS], and perfusion imaging are also used for investigation of dementia often in a research context. DWI/DTI techniques measure the integrity of tissue using primarily two types of measures, fractional anisotropy (FA) and mean diffusivity (MD) or apparent diffusion coefficient (ADC). Reduced FA and increased MD/ADC are considered to be markers of neuronal fiber loss and reduced gray matter and white matter integrity. MRS is a noninvasive neurochemical technique allowing the measurement of biological metabolites in target tissue that has been used in studies of brain aging, neurodegeneration, and dementia. Two major metabolites that often show alterations in patients with dementia include: (1) N-acetylaspartate (NAA), a marker of neuronal integrity; and (2) myo-inositol (mIns), a measure of glial cell proliferation and neuronal damage. However, other MRS analyte signals can also provide information related to membrane integrity and metabolism. Cerebral perfusion is also commonly measured in studies of neurodegeneration and dementia, including with MRI using either dynamic susceptibility contrast enhanced MRI or arterial spin labeling (ASL).32,33 or using SPECT or PET techniques (discussed below). MRI can also be used to measure brain function. Functional MRI (fMRI) measures brain activity...
during a cognitive, sensory, or motor task or at rest by measuring blood flow and blood oxygen levels. The primary outcome measured in most fMRI studies is blood oxygenation level dependent (BOLD) contrast signal in which regional brain activity is measured via changes in local blood flow and oxygenation. Under normal conditions activity-related brain metabolism is tightly coupled to regional blood oxygenation and flow (i.e., blood flow increases to keep the regional blood oxygen level high during brain activation and associated increases metabolic demand). Therefore, the BOLD signal is a useful measure for brain activation. However, altered coupling of neuronal metabolism and blood flow due to brain atrophy and/or hypoperfusion may cause alterations in the BOLD signal. Therefore, fMRI studies in older and demented patient populations with brain atrophy should be carefully evaluated and interpreted with these considerations in mind. fMRI studies often evaluate brain activity during cognitive or functional motor tests. In addition to estimates of regional task-related brain activity, quantification of brain networks can provide a unique measure of brain activity. Techniques for quantifying brain connectivity from fMRI data have recently been developed and applied in studies of brain aging during functional activation (i.e., during performance of tasks), as well as during a “resting” or “task free” state.

SPECT and PET use radiolabeled ligands to measure perfusion, metabolic, and neurochemical processes in vivo. SPECT is primarily used to evaluate brain perfusion in studies of neurodegeneration and dementia. Multiple types of PET ligands have been utilized in studies of dementia, including: (1) [18F]fluorodeoxyglucose (FDG), which measures brain glucose metabolism; (2) tracers that assess brain protein deposits, most commonly to measure amyloid deposition (e.g., [11C]Pittsburgh Compound B (PiB), [18F]florbetapir, others); (3) tracers that assess neurotransmitter systems (i.e., dopamine, serotonin, acetylcholine [ACh], etc.) by binding to neurotransmitter receptors, neurotransmitter transporters, or other associated proteins (e.g., catalytic or metabolic enzymes); and (4) tracers that measure the level of activated microglia (e.g., [11C]PK11195, [11C]DAA1106, [11C]PBR28, others). PET studies allow for an assessment of functional changes in brain metabolism and neurotransmitter and other protein levels, which can provide important information about degenerative changes occurring in the brains of patients.

**Neuroimaging Biomarkers of Degenerative Diseases and Dementias**

**Alzheimer’s Disease and Prodromal Stages**

The most widely used neuroimaging technique to investigate structural changes and neurodegeneration in AD is structural MRI. MRI estimates of regional volumes, extracted using either manual or automated techniques, as well as global and regional tissue morphology, show the presence of significant brain atrophy in AD patients, following an anatomical distribution similar to the stage-specific neuropathological pattern reported by Braak and Braak. Several structural MRI studies have investigated atrophy in AD and found a pattern of widespread atrophy, including in the MTL and lateral temporal lobe (LTL), medial and lateral parietal lobe, and the frontal lobe, with relative sparing of the occipital lobe and sensory-motor cortex. AD patients have been shown to have intermediate atrophy between AD patients and healthy older controls (HC), supporting this as an intermediate clinical stage between healthy aging and AD. MCI patients tend to have more focal reductions in volume and gray matter density than AD patients, particularly in the more clinically mild patients, in the entorhinal cortex and hippocampus, as well as focal cortical atrophy particularly in the temporal, parietal, and frontal lobes. MRI measures of volume, morphometry, and rates of brain atrophy have also shown promise in predicting MCI to AD progression, with significantly reduced hippocampal and entorhinal cortex volumes, as well as reduced cortical thickness in the medial and lateral temporal cortex, parietal lobes, and frontal lobes, in patients destined to convert from MCI to probable AD (MCI-converters), up to 2 years prior to clinical conversion, relative to MCI patients that remain at a diagnosis of MCI (MCI-stable).

Advanced MRI techniques have also been used in studies of patients with AD, MCI, and older adults at risk for AD. DWI/DTI studies have indicated that AD patients have reduced FA and increased diffusion relative to HCs in many white matter structures throughout the brain, with MCI patients showing intermediate changes. Furthermore, DTI measures showed significant white matter changes in older adults at risk for dementia due to subjective cognitive decline relative to those without significant complaints. MRS techniques demonstrated that AD patients have decreased NAA levels and increased mIns relative to HCs throughout the brain, with MCI patients showing intermediate changes. MCI patients have also been shown to have reductions in NAA relative to HC, although NAA values tend to be intermediate between those seen in AD and HC participants. Studies of brain perfusion with MRI have consistently demonstrated decreased perfusion or “hypoperfusion” in patients with AD, particularly in temporoparietal regions, as well as frontal, parietal, and temporal cortices, whereas MCI patients showed decreased brain perfusion in the medial and inferior parietal lobes.

Results from fMRI studies in AD and MCI patients have shown conflicting results. Most studies with AD patients have shown decreased or even absent activation relative to HCs in the MTL, posterior cingulate, parietal lobe, and frontal lobe during episodic memory encoding and recall tasks.
Furthermore, some studies in MCI patients have shown decreased activation relative to HC during episodic memory encoding and recall tasks. However, other studies in both AD and MCI showed increased activation during cognitive tasks. Interestingly, the level of disease severity of patient populations may explain some of these conflicting findings. Increased activation may represent a compensatory mechanism engaged to assist with successful completion of the task in less impaired patients (particularly those with MCI), while more impaired patients, especially those with advanced atrophy, show decreased activation during tasks. Patients at risk for progression to AD due to genetic background also show altered hippocampal activation during episodic encoding and recall, as well as altered activation during working memory tasks.

Functional connectivity studies have also demonstrated alterations in patients with AD and MCI, including decreased connectivity in task-related and resting-state networks. In particular, a network of brain regions that are deactivated upon task initiation that includes the medial parietal lobe, MTL, and medial frontal lobe, which is referred to as the default mode network (DMN), shows decreased connectivity in patients with AD and MCI, including decreased connectivity in task-related and resting-state networks.
Patients with logopenic aphasia show relatively localized atrophy in the posterior temporal lobe and temporoparietal regions with greater atrophy observed in the left hemisphere than in the right. Studies demonstrated a significantly more atrophy in posterior cortical regions (parietal lobe, occipital lobe) than seen in other forms of AD (arrows). Patients with logopenic aphasia show relatively localized atrophy in the posterior temporal lobe and temporoparietal regions with greater atrophy observed in the left hemisphere than in the right (arrows). (Adapted from McGinnis et al.)

PET imaging studies with tracers that bind to cerebral amyloid have shown increased amyloid deposition in neuropathological studies, including the frontal, temporal, and parietal lobes, posterior cingulate, and precuneus. Across [11C]PiB studies, 96% of AD patients showed significant amyloid accumulation, measured as a "positive" [11C]PiB signal, while nearly two-thirds of patients with MCI showed significant amyloid accumulation. In addition, MCI patients with significant amyloid accumulation have a higher likelihood of future conversion to AD. Longitudinal assessments of amyloid using [11C]PiB in AD and MCI patients have shown minimal increases in [11C]PiB signal over 1 to 2 years in patients who showed significant [11C]PiB signal at baseline. However, in patients who do not show significant amyloid deposition at baseline, additional amyloid accumulation may be possible. Thus, researchers have tentatively concluded that amyloid deposition occurs early in the disease and by the time sufficient cognitive decline for a diagnosis of AD occurs, brain amyloid burden is relatively stable and increased deposition is minimal. Finally, patients at risk for progression to AD due to genetic background also show higher amyloid accumulation. Given the results of amyloid PET studies to date, it is noteworthy that in 2011 the United States Food and Drug Administration approved [18F]Florbetapir (Amyvid, Eli Lilly & Co., Indianapolis, IN) for clinical assessment of cerebral amyloid in the context of cognitive decline.

In addition to evaluating cerebral metabolism and the presence of amyloid, researchers have investigated specific alterations in neurotransmitter systems and neuroinflammation in AD and MCI patients using PET. Using PET techniques with tracers specific for acetylcholinesterase (AChE) as a surrogate measure for ACh synaptic density, significant reductions in binding were found in AD and MCI, particularly in
the temporal lobe. Studies in AD patients have also shown decreases in GABA, serotonin, and dopamine synaptic densities, whereas MCI patients have been shown to have deficits in serotonergic neurotransmission only. Studies of activated microglia have shown mixed results in patients with MCI and AD. Some studies demonstrated significantly elevated global and regional activated microglia in patients with AD relative to HCs, while other studies have shown minimal signal in AD and MCI relative to HCs. These differences likely reflect small samples and conflicting quantification methodologies. Future studies are needed to elucidate the role of activated microglia in AD and MCI, as well as utility of this class of PET tracers as a biomarker of immune status in neurodegenerative disorders.

Overall, neuroimaging studies have been useful for quantifying ongoing neuropathological changes in patients with AD, as well as in the prodromal stages of disease. Measures of brain atrophy, brain function and connectivity, brain perfusion and metabolism, and levels of amyloid have shown progressive changes associated with the development and progression of AD. Future studies utilizing newer techniques and in less-affected patient populations will be important for further understanding AD pathology, early disease detection, and the development of targeted therapies.

Familial and Atypical Alzheimer’s Disease

Neuroimaging studies in familial AD patients (i.e., those with mutations in APP, PSEN1, or PSEN2) have shown greater brain atrophy, faster longitudinal atrophy rates, white matter changes measured using DTI, reduced brain metabolism, and increased brain amyloid, in affected patients and in presymptomatic mutation carriers relative to noncarriers. Overall, the use of biomarkers in the study of familial AD has shown similar neuropathological changes as seen in late-onset AD, in both presymptomatic and symptomatic familial AD patients. Studies in these patients may provide information relevant to the role of biomarkers for late-onset AD, as well as to provide sensitive measures for detecting disease-related changes and monitoring disease progression in patients with familial AD. However, it is also noteworthy that in some cases the profile of biomarkers in familial AD patients can differ from that observed in late-onset AD. For example, some familial AD patients may show amyloid deposition in the striatum, a finding which is not often observed in late-onset AD. Future studies to explore the similarities and differences in familial and sporadic AD pathology will provide important information, such those associated with the Dominantly Inherited Alzheimer Network (DIAN).

Sporadic AD usually presents with changes in memory. However, a few related disorders have been identified with atypical presentations (atypical AD), including PCA and logopenic aphasia. Both diseases show widespread amyloid deposition and neurofibrillary tangles, which supports the theory that these disorders are AD dementias despite their atypical clinical presentation. Neuroimaging studies of PCA have demonstrated notable atrophy in posterior brain regions, including in the posterior temporal, parietal, and occipital lobes. A DTI study of white matter integrity also showed notable atrophy of the ventral visual processing stream, with reduced FA in the bilateral inferior longitudinal fasciculus and inferior fronto-occipital fasciculus. Patients with PCA have also been shown to have severe hypoperfusion in occipitoparietal regions, but increased perfusion in frontal, anterior cingulate, and mesio-temporal regions. Finally, PCA patients show positive binding of [11C]PiB with a traditional AD-like pattern, except for more signal than AD patients in the occipital lobe.

Structural MRI studies in logopenic aphasia have shown significant degeneration of the left posterior superior temporal lobe, temporoparietal junction, inferior parietal lobe, posterior cingulate, precuneus, and MTL. In more severe patients, atrophy was also observed in left anterior temporal lobe regions, along the sylvian fissure and into the frontal lobe, as well as in regions of the right temporal and parietal lobes. DTI studies in logopenic aphasia have also shown atrophic changes, including reduced white matter integrity in the left temporoparietal junction and bilateral (but left > right) inferior longitudinal fasciculus, uncinate fasciculus, superior longitudinal fasciculus, and other subcortical projections. SPECT and FDG PET studies have shown reduced perfusion and brain metabolism in the left temporoparietal lobe, respectively. In addition, a recent study demonstrated increased [11C]PiB uptake in patients with logopenic aphasia, suggesting the presence of significant cerebral amyloid.

Cerebral amyloid angiopathy is primarily characterized by vascular pathology on structural imaging. Patients with CAA typically show cerebral microhemorrhages, often at the cortical gray matter/white matter interface and/or in cortico-subcortical junctions of the frontomesial, fronto-orbital, and parietal lobes, microbleeds found predominately in anterior cortical regions, and other ischemic related changes (i.e., white matter lesions and infarcts). A functional MRI study of CAA patients also demonstrated altered vascular function, including reduced vascular reactivity to visual stimulation in the presence of normal blood flow. Studies with SPECT imaging showed hypoperfusion in parietal, temporal, and frontal lobes in patients with CAA. Finally, a PET study with [11C]PiB in patients with CAA demonstrated significant tracer uptake, supporting the presence of extensive cerebral amyloid deposition.

Vascular Cognitive Impairment and Dementia

A few studies have evaluated the extent of brain structural and functional changes in vascular dementia and VCI using in vivo neuroimaging techniques. Although the definitions of vascular dementia and VCI vary significantly across studies, samples of patients with subcortical ischemic vascular dementia (SVWD) and leukoaraiosis, which is extensive white matter pathology identified using MRI, are most commonly evaluated. Several studies have investigated patients with SVWD and other patients with vascular dementia using structural MRI techniques and shown that SVWD patients and patients with leukoaraiosis show greater number of white matter lesion than cognitively healthy older adults without subcortical infarcts and patients with AD.
presence of more white matter lesions is also significantly associated with impaired cognition, particularly in executive function and processing speed domains, as well as a greater dementia severity and the presence of cognitive complaints.\textsuperscript{136,138–140} Patients with SIVD and leukoaraiosis also show significant gray matter, white matter, and hippocampal atrophy relative to HCs,\textsuperscript{132,134,135,137,141–144} which has also been linked to the extent of white matter lesion pathology.\textsuperscript{133–136,145,146} Only a limited number of studies have investigated structural MRI changes in patients in earlier stages of vascular dementia, such as vascular-related MCI.\textsuperscript{133,134,136,143} Seo and colleagues reported cortical thinning in patients with MCI linked to subcortical ischemia, particularly in frontal, temporal, and occipital regions.\textsuperscript{143} Patients with vascular-associated MCI also show a significantly greater extent of white matter lesions than HC, the presence of which is associated with progression to dementia.\textsuperscript{133} Studies utilizing DTI have demonstrated significant changes in SIVD and leukoaraiosis patients, even in normal-appearing white matter.\textsuperscript{147–154} In fact, DTI measures of decreased white matter integrity have shown significant association with dementia severity, cognition, motor function, and cerebral atrophy.\textsuperscript{147,148,150–154} A few studies have also evaluated fMRI measures in patients with vascular dementia, in particular SIVD. Two studies evaluated task-related fMRI in SIVD patients and demonstrated reduced activation and altered brain blood flow-metabolic coupling during an executive function and motor task, respectively.\textsuperscript{155,156} Finally, a study by Sun and colleagues showed altered posterior cingulate cortex functional connectivity in SIVD patients using resting-state fMRI.\textsuperscript{157} Schuff and colleagues assessed brain perfusion in SIVD using ASL and demonstrated reduced cerebral blood flow, particularly in frontal and parietal lobes.\textsuperscript{158} These results support previous studies utilizing PET and SPECT techniques, which showed reduced cerebral perfusion and metabolism in patients with vascular dementia.\textsuperscript{159,160} In fact, FDG PET studies have shown hypometabolism in a scattered pattern in cortical and subcortical regions in vascular dementia.\textsuperscript{161} Finally, amyloid PET tracers show minimal binding in the majority of patients with vascular dementia in the absence of CAA.\textsuperscript{162} Neuroimaging studies in vascular dementia have demonstrated notable changes in brain atrophy, function, perfusion and metabolism secondary to vascular pathology. Prospective studies evaluating patients in earlier stages of disease would be useful to identify the progressive changes associated with the development of vascular dementia, as well as the effect of any interventional treatments. In addition, studies of patients with vascular pathology and other types of comorbid pathology (AD, FTD, etc.) will provide the opportunity to assess the overlap of multiple diseases and the relative contribution of various pathologies to cognitive decline.

**Frontotemporal Dementia**

Behavioral variant FTD is characterized primarily by changes in personality and behavior and is caused by accumulation of pathological tau protein or TDP-43 or in rare cases by changes in the fused in sarcoma (FUS) protein.\textsuperscript{13,16,17} Genetic forms of bvFTD can be linked to mutations in the tau gene (\textit{MAPT}), which results in tau pathology, the progranulin gene (\textit{GRN}), which results in TDP-43 pathology, as well as several other genes.\textsuperscript{13,16,17} Generally, bvFTD patients show widespread atrophy in the frontal lobes, anterior cingulate, anterior insula, and thalamus (\textit{→ Fig. 3B}).\textsuperscript{13,120,163,164} Longitudinally,
faster atrophy rates are observed in the frontal lobes.120,165 Some differences in atrophy are observed in bvFTD based on underlying pathology. bvFTD due to Pick’s disease shows atrophy in the prefrontal cortex, temporal lobes, anterior cingulate and insula, which is typically bilateral but with slightly greater atrophy on the left than right.17,166 The frontal atrophy in bvFTD patients with Pick’s disease is usually greater than that seen in other bvFTD forms, such as CBD, patients with MAPT mutations, and those with underlying TDP-43 pathology.17,167 Patients with MAPT mutations tend to be a heterogeneous group with atrophy observed in the frontal and temporal lobes, insula, anterior cingulate, parietal lobe, basal ganglia, and brainstem.17,168 Furthermore, patients with MAPT mutations may show more temporal lobe atrophy than other bvFTD forms.13,169 Patients with bvFTD with TDP-43 pathology show widespread frontal, temporal, and parietal atrophy, which tends to be asymmetric but either side can show predominance.17,166,170,171 The parietal atrophy tends to be more severe in patients with TDP-43 bvFTD variants than those caused by tau pathology.17 Patients with mutations in the GRN gene show a similar pattern of frontal, temporal, and parietal atrophy, but may show a greater asymmetry than bvFTD patients with TDP-43 who do not have a GRN mutation.172 Finally, bvFTD patients with underlying FUS pathology show a unique pattern of severe caudate atrophy, along with similar frontal atrophy to that seen in the other bvFTD forms.17,173 DTI studies of white matter integrity in bvFTD have demonstrated reduced FA in frontal and temporal white matter, including in the uncinate fasciculus, anterior cingulum, superior longitudinal fasciculus, and inferior longitudinal fasciculus relative to HC.128,174,175 Patients with bvFTD show greater frontal lobe white matter changes than AD patients, including in the anterior cingulum, anterior corpus callosum, and uncinate fasciculus.175,176 DTI studies in bvFTD patients with MAPT and GRN mutations have also shown reduced white matter integrity throughout the frontotemporal white matter.177 Studies of task-related fMRI activation in bvFTD have shown altered activation patterns during working memory and emotional processing tasks, including reduced frontal and parietal activation during working memory178 and emotion-specific abnormalities in frontal and limbic regions, as well as altered activation in posterior regions (i.e., fusiform gyrus, inferior parietal cortex) during an implicit face-expression task.179 Resting-state fMRI has also demonstrated altered functional connectivity in patients with bvFTD, particularly in the salience network, which is a network of regions involved in filtering sensory and emotional stimuli and directed attention that includes the anterior cingulate cortex, bilateral insula, dorsolateral prefrontal cortex, supplementary motor area, and other temporal, frontal, and parietal cortical regions.180 Patients with bvFTD show decreased connectivity in the dorsal and ventral salience network, including in the basal ganglia and frontal lobe, but increased connectivity in the precuneus relative to HC.181–183 Relative to AD patients, bvFTD patients show an opposite pattern of functional connectivity, with decreased connectivity in the salience network and increased connectivity in the DMN.181,184 Alterations in connectivity of other regions has also been reported, including in an attention/working memory network, which showed reduced connectivity with the DMN, and an executive network, as well as in cingulate and frontal white matter regions.177,182 Patients with MAPT mutations also show alterations in connectivity of the DMN, with increased connectivity in the medial parietal lobe and reduced connectivity in the lateral temporal and medial prefrontal cortices.185 Patients with bvFTD showed reduced cerebral perfusion, primarily in frontal and temporal lobes, in studies utilizing both SPECT and ASL techniques.120,128,163,164,174,186 FDG PET studies of brain metabolism in bvFTD have also demonstrated notable hypometabolism in frontal and temporal regions.120,128,163,164 Studies with amyloid tracers (i.e., [11C] PiB) showed minimal binding in patients with bvFTD.131 The semantic variant of primary progressive aphasia (PPA), semantic dementia (SD), features language difficulties with fluency, anoma, and single-word comprehension and is most commonly associated with TDP-43 pathology. Patients with SD show asymmetrical atrophy of the temporal lobes, most commonly left > right, particularly in anterior and inferior temporal lobe regions, including the temporal pole, perihinal cortex, anterior fusiform, hippocampus, and amygdala (►Fig. 3A).13,16,187–189 More severe patients may also show atrophy in parts of the superior and posterior left temporal lobe, regions of the left frontal lobe, left insula, and left anterior cingulate, as well as increasing atrophy in the right temporal lobe.13,190 Longitudinally, SD patients show progressive atrophy of the left temporal lobe, followed by the right temporal lobe.13,191 DTI techniques have shown reduced white matter integrity in bilateral temporal lobes (left > right), including in the inferior longitudinal fasciculus, left parahippocampal white matter, and in the uncinate fasciculus, with the lowest FA values seen in the left anterior temporal lobe.125,174,175 fMRI studies of SD patients have shown altered activation patterns during a variety of tasks, including during sound processing, autobiographical memory, and surface dyslexia.192–194 Resting-state functional connectivity studies have also shown decreased connectivity of frontotemporal and frontolimbic circuitry, but increased connectivity in local networks of the prefrontal cortex in SD patients relative to HC.195 SPECT and PET studies of SD patients demonstrated reduced perfusion and metabolism primarily in the left anterior temporal lobe,13,120,126 while a study with [11C]PiB showed minimal binding.126 The nonfluent variant of PPA, progressive nonfluent aphasia (PNFA), is more heterogeneous than SD featuring speech production impairment with aggrammatism, phonemic errors, anoma, sentence comprehension impairment, and potentially apraxia of speech. Progressive nonfluent aphasia can be caused by either tau or TDP-43 pathology, the latter of which does not show apraxia of speech.13 Patients with PNFA show atrophy primarily in anterior perisylvian regions, including in the left inferior frontal lobe, insula, and premotor cortex, with further involvement of other frontal lobe regions, the temporal and parietal lobes, as well as the caudate and thalamus in later disease stages (►Fig. 3C).13,16,190,196,197
Interestingly, PNFA patients with underlying Pick’s disease (tau) pathology have more severe temporal lobe atrophy than other forms, while those with a GRN mutation (TDP-43 pathology) show notable atrophy in the left lateral temporal lobe. DTI studies in PNFA patients demonstrated moderate decreases in white matter integrity relative to HC in the left arcuate fasciculus, most especially in the frontoparietal component, in the superior motor pathway, and in left perisylvian, inferior frontal, insular, and supplemental motor area regions. A study utilizing fMRI in PNFA patients demonstrated reduced activation in the left inferior frontal lobe during sentence reading and comprehension relative to HC. FDG PET studies have demonstrated hypometabolism in left inferior frontal gyrus, frontal operculum, insula, premotor cortex, and supplementary motor area in PNFA patients. Studies with [11C]PiB showed minimal binding in patients with PNFA, however, some signal was observed in those with underlying Pick’s disease pathology. Finally, PNFA patients show reduced striatal dopaminergic signal with a tracer targeting pre-synaptic dopaminergic transporters.

Frontotemporal dementia with motor symptoms has multiple forms, including CBD, PSP, FTD with motor neuron disease (FTD-MND), and FTD with ALS (FTD-ALS). These diseases can present with behavioral or language symptoms (typically PNFA), but usually they present with behavioral symptoms. However, all of these disorders also feature motor dysfunction. Corticobasal degeneration and PSP are caused by tau pathology, while FTD-MND and FTD-ALS are associated with TDP-43 pathology. Structural imaging studies in CBD and PSP have shown significant atrophy in the posterior frontal cortex in both disorders, with more atrophy in the basal ganglia and faster longitudinal decline in whole brain volume in CBD than PSP. Atrophy in CBD is also typically asymmetrical, while atrophy in PSP is usually symmetrical. DTI studies in CBD demonstrated a loss of white matter integrity in the motor thalamus, precentral and postcentral gyrus, and bilateral supplementary motor area, while PSP patients showed decreased white matter integrity in the anterior part of the thalamus, cingulum, primary and supplementary motor areas, and fronto-orbital white matter. ASL studies in CBD have also shown reduced cerebral perfusion in the right hemisphere. SPECT studies have demonstrated reductions in neurotransmitters in both CBD and PSP, with reduced dopaminergic transporter binding in the striatum and reduced acetylcholine transporter binding in the anterior cingulate and thalamus relative to HC. FDG PET studies in CBD and PSP also showed cerebral hypometabolism, with reduced metabolism in cortical regions contralateral to the physically affected side in CBD and hypometabolism in the prefrontal cortex, caudate, thalamus, and mesencephalon in PSP.

FTD-MND and FTD-ALS are both primarily linked to TDP-43 pathology (although a few FTD-MND patients may show FUS pathology) and feature behavioral or language deficits along with motor dysfunction. Patients with FTD-MND or FTD-ALS show frontal and temporal lobe atrophy, in addition to atrophy in the anterior cingulate, occipital lobe, and precentral gyrus in FTD-ALS only. DTI studies have shown decreased white matter integrity relative to HC in frontal and temporal regions, including the corpus callosum, corticospinal tract, cingulum, inferior longitudinal fasciculus, inferior fronto-occipital fasciculus, and uncinate fasciculus, which was associated with poorer performance on cognitive tasks. Task-related and resting-state fMRI and functional connectivity studies have also shown alterations in brain function and connectivity in patients with FTD-ALS. Reduced activation in FTD-ALS patients measured using PET and fMRI was observed in the frontal lobe, insula, and thalamus during an executive task and in the frontal lobe, anterior cingulate, supramarginal gyrus, temporal lobe, and occipitotemporal regions during a verbal fluency task. Reduced frontal activation during an emotional task was also observed in nondemented FTD-ALS patients. Reorganization of motor networks and decreased functional connectivity of a sensorimotor network, the DMN, and a frontoparietal network were also seen in resting-state studies of FTD-ALS patients. Patients with FTD-MND demonstrated reduced perfusion in SPECT studies in the frontal lobe, including the premotor cortex and precentral gyrus, as well as the temporal lobe, cingulate, insula, thalamus, and striatum. Patients with FTD-ALS also show hypoperfusion in similar areas of the frontal and temporal lobes, which correlates with impaired cognition. FDG PET studies in FTD-MND patients demonstrated reduced metabolism in the frontal, anterior, and medial temporal lobe, basal ganglia, and thalamus (Fig. 4), whereas patients with FTD-ALS show hypometabolism in the frontal lobe, superior occipital lobe, and thalamus. Patients with FTD-ALS also show reduced serotonin binding in the frontal lobe, as well as a reduced number of GABA-A receptors in the frontal lobe, superior temporal lobe, parietal lobes, occipital lobe, and insula. Some forms of FTD-MND and FTD-ALS are caused by genetic mutations in chromosome 9 (C9ORF72) or GRN. Patients with FTD-MND carrying a mutation in chromosome 9 have more thalamic atrophy than those with FTD-MND without the chromosome 9 mutation, as well as greater frontal lobe, temporal lobe, insular, and posterior cortical atrophy than seen in FTD patients with other mutations.

In sum, neuroimaging studies in FTD have been useful for identifying and quantifying structural and functional changes in the brain during disease, including frontal and temporal atrophy, altered brain function and connectivity, reduced cerebral perfusion and metabolism, and changes in neurotransmission. However, additional studies in larger cohorts to better characterize and differentiate the various FTD subtypes, as well as the overlap between FTD and ALS, are needed.

**Amyotrophic Lateral Sclerosis**

Amyotrophic lateral sclerosis (ALS) is a progressive degenerative motor disease that includes cognitive changes in up to 63% of patients (FTD-ALS, see above section). However, patients with ALS without cognitive symptoms also show structural and functional changes in the brain, although usually these changes are less severe than those in ALS patients with cognitive decline. Patients with ALS show...
progressive atrophy in motor and extramotor regions, most especially in the precentral gyrus.\textsuperscript{211,229–231} DTI studies demonstrated widespread loss of white matter integrity, including in the corticospinal tract, the posterior limb of the internal capsule, cingulum, midposterior corpus callosum, and in frontal and temporal white matter tracts, such as the uncinate fasciculus, inferior longitudinal fasciculus, and inferior fronto-occipital white matter.\textsuperscript{211–213,232–234} Functional MRI studies have shown altered brain activation in ALS patients during motor tasks, including increased activation in motor and premotor areas, the supplementary motor area, inferior parietal lobes, superior temporal lobes, and cerebellum during movement and increased activation in basal ganglia, cerebellum, and brainstem during motor learning.\textsuperscript{211,235–238} During a sensory task, patients with ALS had reduced activity in primary and secondary sensory areas but increased activation in associative sensory areas.\textsuperscript{211,239} Altered activation during emotional processing in non-demented ALS patients was also seen, with increased activation in the left hemisphere but reduced activation in the right frontal lobe.\textsuperscript{218} Changes in functional connectivity in patients with ALS have also been observed. Studies have found mixed findings, with decreased connectivity of a sensorimotor network, the DMN, and an interhemispheric motor network seen in some studies but increased connectivity in sensorimotor, premotor, prefrontal cortex, and thalamic networks seen in other studies.\textsuperscript{211,219,240,241} MRS studies have shown alterations in patients with ALS, including decreased NAA and increased choline, glutamate, glutamine, and mlns in the corticospinal tract, posterior limb of the internal capsule, and periventricular white matter, as well as a decreased NAA/choline ratio in the thalamus, basal ganglia, middle cingulate, and frontal and parietal lobes.\textsuperscript{211,242–245} SPECT and PET studies in ALS have observed reduced cortical perfusion and metabolism, which was associated with reduced cognition even in nondemented ALS patients.\textsuperscript{211,246–248} Dopaminergic and GABAergic cell loss in the basal ganglia and substantia nigra has also been reported.\textsuperscript{211,226,249} Finally, an increase in binding of a PET tracer that labels activated microglia, $[^{11}\text{C}]$PK-11195, was observed in ALS patients in the corticospinal tract and extramotor regions with the greatest binding observed contralateral to the physically affected side.\textsuperscript{211,250,251}

**Parkinson’s Disease/Dementia with Lewy Bodies**

Parkinson’s disease (PD) is a degenerative motor disease that may or may not feature cognitive impairments. However, up to 80% of PD patients will eventually develop cognitive symptoms.\textsuperscript{21} Pathological and clinical differences between Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB) are minimal and subject to debate. Thus, imaging findings in these disorders (PDD/DLB) will be discussed together, followed by a discussion of imaging in PD without dementia. Patients with PDD/DLB show fluctuations in attention, executive function, and higher order visual function, in addition to motor symptoms which are the result of widespread deposition of α-synuclein. Structural imaging studies have shown widespread atrophy in cortical and subcortical regions in patients with PDD/DLB, including in the temporal, parietal, and frontal lobes, in the MTL (hippocampus, amygdala, entorhinal cortex), basal ganglia, thalamus, hypothalamus, substantia nigra, insula, and occipital lobe.\textsuperscript{11,20,21,181,252–257} Although atrophy patterns are similar in PDD and DLB, some studies have suggested increased fronto-temporal atrophy but less caudate atrophy in DLB patients relative to PDD.\textsuperscript{20,258,259} In addition, amyloid positive PDD/DLB patients show more cerebral atrophy than PDD/DLB patients.
who are amyloid negative. Longitudinally, patients with PDD/DLB show faster rates of cerebral atrophy than PD patients without dementia and HC, particularly in regions of the medial and lateral temporal lobe, as well as occipitotemporal areas. DTI studies in PDD/DLB demonstrated reduced white matter integrity in the frontal, temporal, and parietal lobes, pons, thalamus, precuneus, caudate, corpus callosum, and inferior longitudinal fasciculus. Some studies again showed greater pathology in DLB than PDD, with more reduced FA in the bilateral posterior temporal lobe, posterior cingulate, and bilateral visual association areas in DLB. MRS studies in PDD patients have shown reduced NAA/creatinine and glutamine/glutamate ratios in the posterior cingulate and bilateral hippocampus. Studies of patients with PDD/DLB utilizing fMRI techniques demonstrated reduced activation in the lateral occipitotemporal lobe during visual motion and in the ventral occipitotemporal lobe during face matching, but increased activation in the superior temporal sulcus during the latter task. Reduced activation in visual areas was also seen during presentation of a simple visual motion stimuli. Alterations in brain activation during executive function paradigms in patients with PDD/DLB have also been observed, although mixed findings have been reported including increased activation and decreased activation in the prefrontal cortex during various tasks. Resting-state functional connectivity studies have also shown changes in brain connectivity in patients with PDD/DLB, including reduced global and local cortico-cortical connectivity. Other studies have shown altered connectivity of the precuneus, with increased connectivity of the precuneus with regions of the dorsal attention network and putamen, but decreased connectivity of the precuneus with the DMN and visual cortices. ASL and SPECT studies have shown reduced cortical perfusion in posterior cortical areas in PDD/DLB patients, including in occipital and temporoparietal regions. Hypometabolism has also been reported in FDG PET studies of PDD/DLB patients, particularly in the basal ganglia, cerebellum, and frontal, temporal, parietal, and occipital lobes with relative sparing of metabolism in the MTL. Furthermore, occipital lobe hypometabolism was associated with visual hallucinations in DLB patients. PET studies with amyloid tracers (i.e., [11C]PiB) have shown positive amyloid binding in ~40% of PDD/DLB patients (50% of DLB, 30% of PDD), with a similar anatomical distribution to the pattern seen in AD patients. Reduced dopaminergic transporter binding in the basal ganglia has also been observed in PDD/DLB patients, with decreased binding in the caudate, which is associated with cognitive symptoms, and decreased binding in the putamen, which is associated with motor symptoms. Decreased cholinergic neurotransmission has also been seen in patients with PDD/DLB throughout the cortex, particularly in medial occipital and posterior cortical regions, which is more severe than changes in patients with PDD/DLB, including reduced global and local cortico-cortical connectivity. Fig. 5 Dopaminergic deficits in Parkinson’s disease (PD) relative to healthy adults. Reduced dopaminergic neurotransmission is observed in patients with PD relative to healthy adults (“healthy”), particularly in the posterior putamen (arrows). 123I-β-CIT labels the dopamine transporter (DAT), which is located presynaptically on dopamine-releasing terminals. 11C-DTBZ labels the vesicular monoamine transporter (VMAT) and 18F-dopa labels amino acid decarboxylase (AADC). Both of these molecules are found in neuron terminals releasing dopamine. Overall, these three positron emission tomography (PET) tracers provide sensitive measures of the density of neuron terminals releasing dopamine in the striatum. (Adapted from Brooks et al. 2013)
seen in PD patients without dementia and AD patients.\textsuperscript{21,128,131,258,283–287}

Patients with PD without dementia also show atrophic and functional brain changes, although they tend to be milder than those seen in PDD/DLB patients. Some studies have shown gray matter atrophy in the left anterior cingulate, left gyrus rectus, left parahippocampal gyrus, and right frontal lobe in PD patients, while other studies show minimal or no atrophy.\textsuperscript{252} Mild hippocampal atrophy has also been observed, although significantly less atrophy than seen in PDD/DLB and AD.\textsuperscript{21,288–290} Further, patients with PD show a slightly faster cortical atrophy rate than HC, particularly in regions of the cingulate, occipitotemporal lobe, insula, hypothalamus, nucleus accumbens, and hippocampus.\textsuperscript{21,291} Studies utilizing PET techniques have most commonly been reported in PD. Using FDG PET, patients with PD showed reduced metabolism in frontal, temporal, parietal, and occipital lobes, as well as in the basal ganglia and thalamus.\textsuperscript{21,278,279} Parietal and frontal metabolism also shows longitudinal decreases over time.\textsuperscript{21,293} However, PET studies with [\textsuperscript{11}C]PiB have shown no significant binding in PD patients without dementia.\textsuperscript{131} PET studies evaluating different neurotransmitter systems have also been widely used in PD patients, including assessments of dopaminergic, serotonergic, cholinergic, GABAergic, and opioid neurotransmission. Reduced dopaminergic neurotransmission in the striatum has been observed in patients with PD, with the most significant changes in the putamen contralateral to the physically affected side (\textsuperscript{\textsuperscript{\textsuperscript{\textsuperscript{\textsuperscript{-Fig. 5}}}}}).\textsuperscript{2,283,294,295} Early in the disease, increased dopaminergic receptor binding has been observed in the putamen, frontal lobe, anterior cingulate, and globus pallidus.\textsuperscript{283,296,297} However, later in the disease course reduced dopaminergic receptor binding is also seen in the thalamus, anterior cingulate, and frontal and temporal lobes.\textsuperscript{283,298,299} Reduced serotonergic neurotransmission in the orbitofrontal cortex, cingulate, putamen, and midbrain has also been reported in patients with PD.\textsuperscript{283,300} Furthermore, ACh neurotransmission is reduced in cortical regions in PD, even early in disease, while increased ACh receptors have been reported in the frontal and temporal lobes.\textsuperscript{283,284,287,301} Decreased GABAergic neurotransmission has also been reported, primarily in the pons and putamen.\textsuperscript{302} while striatal, thalamic, cingulate, and frontal areas show reduced opioid neurotransmission.\textsuperscript{283,303} Finally, increased microglial activation has been observed in patients with PD in both striatal and extra-striatal regions.\textsuperscript{283,304,305}

Overall, studies in patients with PD with or without dementia, as well as D LB patients, have shown significant atrophic, functional, and molecular brain changes. Additional studies in early stage PD-related disorders before cognitive changes will help further the understanding of disease development in relation to phenomenology, as well as the potential for neuroimaging biomarkers to be used in clinical assessment and monitoring of treatments.

**Huntington’s Disease**

Huntington’s disease (HD) is an autosomal dominantly inherited progressive degenerative disease causing motor and cognitive abnormalities. Progressive reductions in striatal volume can be seen in both presymptomatic (pre-HD) and symptomatic (“manifest”) HD patients, even up to 15 to 20 years before the clinical symptoms appear (\textsuperscript{-Fig. 6}).\textsuperscript{306–310} Atrophy of the putamen is greater than that in the caudate early in the disease and later atrophy expands to the globus pallidus and nucleus accumbens.\textsuperscript{306,308,309,311} This striatal atrophy is associated with impaired motor and cognitive function.\textsuperscript{308,311} Atrophy is also seen in other gray matter and white matter regions in both pre-HD and manifest HD, including cerebral thinning throughout the cortex, atrophy in the cingulate and thalamus, and atrophy of the white matter tracts near the striatum, as well as the corpus callosum, posterior white matter tract, and frontal lobe white matter.\textsuperscript{306,312–314} Subcortical and cortical atrophy, specifically in the left superior frontal gyrus, left inferior parietal lobule, and bilateral caudate, has also been shown to be associated with impaired saccade eye movement.\textsuperscript{315} Longitudinally, faster rates of atrophy in the striatum are observed in both pre-HD and manifest HD patients, whereas greater whole brain atrophy rates are observed in manifest HD patients only.\textsuperscript{306,310,312} DTI studies have shown reduced white matter integrity in the frontal lobe, precentral gyrus, postcentral gyrus, corpus callosum, anterior and posterior limbs of the internal capsule, putamen, and globus pallidus in patients with pre-HD and manifest HD.\textsuperscript{316–318} fMRI studies have demonstrated task-induced activation differences in pre-HD and manifest HD patients in the striatum, cingulate, and premotor regions during several cognitive tasks.\textsuperscript{319} Furthermore, decreased activation of the primary motor cortex, medial premotor regions, prefrontal cortex, and parietal lobe, along with increased insula activation were observed during a motor task.\textsuperscript{32} fMRI studies of antisaccade eye movement have also shown altered brain activation in task-related regions.\textsuperscript{320} Studies of resting-state connectivity have shown reduced DMN connectivity in the anterior prefrontal cortex, inferior parietal lobe, and posterior cingulate, as well as reduced connectivity between cortical motor regions and the striatum in pre-HD patients.\textsuperscript{321,322} Functional connectivity during a working memory task was also shown to be altered in patients with pre-HD in regions of the prefrontal cortex, striatum, and frontoparietal regions.\textsuperscript{319} PET studies have also shown alterations in brain metabolism, dopaminergic neurotransmission, and activated microglia in pre-HD and manifest HD patients. Reduced brain metabolism is observed in pre-HD patients, which may be useful for detecting and monitoring disease progression.\textsuperscript{2,323,324} Reduced dopaminergic receptor binding was observed in both cross-sectional and longitudinal studies in pre-HD and manifest HD patients.\textsuperscript{2,325,326} The longitudinal decline in dopaminergic receptors was also associated with decline in both cognition and motor function.\textsuperscript{2,327–329} Studies utilizing [\textsuperscript{11}C]PK-11195 have shown increased activated microglia in the striatum, extrastriatal regions, and the hypothalamus in both pre-HD and manifest HD patients, which correlated with reduced dopaminergic receptor binding, increased motor dysfunction, and predicted time of clinical onset.\textsuperscript{2,330–333}
Overall, neuroimaging studies in patients with HD have shown marked changes in brain structure and function, particularly in striatal regions. Alterations observed in pre-HD patients are particularly interesting, as studies in this population allow for exploration of the progression of disease before the onset of clinical symptoms. Future studies exploring neuroimaging measures in both pre-HD and HD patients will assist with better clinical diagnosis, even prior to disease onset, and monitoring of potential therapeutics in the context of early intervention.

### Multiple Sclerosis

Multiple sclerosis (MS) features motor, sensory, visual, and autonomic system dysfunction due to progressive lesions in cerebral gray matter and white matter. Patients can present with various forms including relapsing-remitting MS (RRMS), many of whom later develop secondary progressive MS, primary progressive MS, and clinically isolated MS syndrome. The most commonly reported neuroimaging feature in MS is focal hyperintense white matter lesions on T2-weighted, FLAIR, and contrast-enhanced MRI scans. T1-weighted hypointense lesions (“black holes”) have also been reported. Patients with MS also show atrophy of the gray matter and white matter, particularly reduced gray matter in the cerebellum, thalamus, subgenual gyrus, middle cingulate cortex, superior frontal lobe, and bilateral temporal and occipital lobes. Gray matter atrophy is predictive of cognitive symptoms and long-term disability. DTI techniques have also shown damage in normal appearing gray matter and white matter, as well as lesion tissues. Loss of white matter integrity in the corpus callosum, corona radiata, superior and inferior longitudinal fasciculi, internal and external capsule, posterior thalamic radiations, cerebral peduncles, and superior cerebellar peduncles was observed and correlated with both motor and cognitive symptoms. In normal appearing white matter, widespread abnormalities are observed, even in the earliest stages, which progress as the disease worsens. Changes in normal appearing gray matter appear later in the disease course, with increased diffusivity and increased or decreased FA depending on phase of gray matter inflammation observed in later-stage patients. In white matter tissue with lesions, significant alterations in white matter integrity are observed in all MS forms except for in primary progressive MS. However, gray matter lesions actually show an increase in FA, which may reflect more inflammation. fMRI studies in MS patients have shown significant alterations in brain activation during cognitive tasks, including during tests of working memory, episodic memory, processing speed, and attention. MS patients show increased activation in the right hemisphere, most especially in the prefrontal cortex, during working memory tasks, as well as widespread increased activation during episodic memory tasks, which was positively associated with increased lesion load. A similar finding of increased activation in the right prefrontal cortex was seen during a test of processing speed. These increases in activation may represent compensatory changes to maintain clinical performance, as patients with...
performance deficits actually show decreased brain activation during episodic memory. In tests of attention, patients showed variable changes in brain activation dependent on clinical stage, with mildly impaired patients showing increased activation and decreased activation observed in those with more severe cognitive impairment.

Resting-state studies have also shown alterations in connectivity in patients with MS, although the findings have been mixed. In patients with primary and secondary progressive MS, decreased connectivity of the DMN is observed, particularly in the anterior cingulate. This decreased connectivity in the anterior cingulate is associated with functional impairments and DTI abnormalities in the corpus callosum and cingulum on DTI measures. A study in RRMS patients showed decreased connectivity of the salience, working memory, sensorimotor, and visual networks, as well as the DMN, increased connectivity of the auditory network, and both increases and decreases in the connectivity of the executive control network. Decreased connectivity was correlated to the extent of disability and lesion load. Altered connectivity between networks was also observed with decreased connectivity between the executive control network and the DMN, but increased connectivity between the executive control network and the salience network. However, other studies have primarily shown increased connectivity in various brain networks. For example, increased connectivity in several motor, sensory, and cognitive networks was observed in RRMS patients, with increased connectivity in frontoparietal networks associated with poorer clinical status. Increased connectivity in the DMN, an attention network, and cognitive control network have also been shown to be associated with impaired cognition. However, a different study demonstrated that increased connectivity in the cerebellum, middle temporal gyrus, occipital pole, and angular gyrus were associated with better cognition. Reorganization of the DMN has also been reported in RRMS patients, with decreased connectivity in midline regions (i.e., anterior and posterior cingulate) and increased connectivity in peripheral posterior brain regions. The conflicting findings in these studies may be related to the type of MS and disease severity of the patient population studied, as well as the brain locations evaluated.

PET studies in patients with MS have shown changes in cerebral perfusion and metabolism, as well as increased microglial activation. Reduced cerebral blood flow in gray matter and white matter is observed in MS patients, which correlates with impaired cognition and a higher level of disability. Hypometabolism is also observed in the thalamus, deep cortical gray matter structures, and the frontal lobe. This hypometabolism is associated with impaired cognition, as well as corpus callosum atrophy (left hemisphere more associated than the right). In longitudinal studies, decreasing cortical metabolism was observed in MS patients, which was associated with disease progression. Studies with [11C]PK-11195 have shown a widespread pattern of activated microglia in both lesion tissue and normal appearing gray matter and white matter. The increased microglial activation observed in cortical gray matter was associated with increased clinical disability.

Studies of neuroimaging biomarkers in MS patients have routinely shown the presence of cerebral lesions in gray matter and white matter regions, along with brain atrophy and alterations in brain function and molecular systems. Future studies in the earliest phases of MS will allow further exploration of the development and progression of the disease, as well as the efficacy of targeted treatments.

**HIV-Associated Neurocognitive Disorder**

HIV-associated neurocognitive disorder (HAND) primarily involves impairments in attention, executive function, motor speed, and memory. Structural MRI studies of patients with HAND showed gray matter atrophy throughout the cerebral cortex, particularly in anterior cingulate, lateral temporal cortex, primary motor and sensory cortices, and frontal and parietal lobes. White matter atrophy and abnormalities are also common. Some patients present with progressive multifocal leukoencephalopathy characterized by focal white matter lesions typically in subcortical regions. Motor and cognitive symptoms are also associated with decreased basal ganglia volume. DTI studies have shown that reductions in white matter integrity in the cortical white matter, corpus callosum, and corona radiata are associated with cognitive impairment. MRS studies of patients with HAND have shown alterations in brain metabolites, including decreased NAA/Creatinine (Cr) and increased choline, mls, choline/Cr, and mls/Cr in the frontal white matter and basal ganglia. In addition, HAND patients with concurrent hepatitis C infection show greater increases in mls/Cr in the basal ganglia than those with only HAND. MRI studies have shown both decreased and increased activation during various cognitive and motor tasks. Specifically, decreased activation during a motor task was observed in HAND patients, while increased activation was observed during attention and working memory tasks in the frontal and parietal lobes. Increased activation was also observed in HAND patients during episodic memory recognition, while decreased activation was observed during episodic encoding in the MT. Finally, decreased activation was observed in the left caudate, left dorsolateral prefrontal cortex, and bilateral ventral prefrontal cortex, while increased activation was observed in the right postcentral/supramarginal gyrus during an executive function task. Functional connectivity has also been evaluated in patients with HAND both during a cognitive task and at rest. A study of task-related connectivity during an executive function task showed reduced connectivity in the caudate, prefrontal cortex, and basal ganglia in HAND patients, while increased connectivity was observed in the caudate and anterior parietal lobe. Resting-state connectivity in the DMN, salience network, and control network is also reduced in patients with HAND. Furthermore, decreased internetwork connectivity has been observed, particularly between the DMN and a dorsal attention network. Studies of perfusion with SPECT and MRI techniques have shown hypoperfusion in patients with HAND, particularly in the inferior lateral frontal lobe.
in inferior medial parietal lobe, and in other frontoparietal regions. \(^{386,387}\) This hypoperfusion was associated with dementia severity. \(^{387}\) Alternatively, hyperperfusion was observed in the posterior inferior parietal white matter and in deep gray matter structures. \(^{386,388}\) Hypometabolism in the cerebral cortex and hypermetabolism in the basal ganglia was also observed in HAND patients using [18F]FDG PET. \(^{389-391}\) Another study observed asymmetrical glucose metabolism in the prefrontal cortex and premotor regions in HAND patients. \(^{392}\) Finally, a PET study utilizing tracers that bind to dopamine transporters (DAT) or D2 receptors observed decreased DAT binding in the putamen and ventral striatum but no difference in D2 receptor binding in HAND patients relative to HC. \(^{393}\) The observed reductions in DAT binding were associated with disease severity. \(^{393}\)

HIV-associated neurocognitive disorder is relatively common in HIV-positive individuals. Imaging studies of this disorder have found significant abnormalities in brain structure, function, perfusion, glucose metabolism, and neurotransmission which likely underlie the observed clinical dysfunction. The advent of retroviral therapies has been shown to alter the observed brain changes associated with HAND; however, additional studies are needed. Additional studies designed to evaluate the clinical significance of imaging techniques in various HIV-positive populations, particularly in those who are treated with retroviral therapies, are ongoing and will provide important information about the nature of cognitive dysfunction in these individuals.

### Prion Protein Diseases

Degenerative disorders and dementias caused by the accumulation of abnormal prion proteins can occur sporadically (sporadic CJD), due to exposure to food (variant CJD) or tissues (iatrogenic CJD) containing the abnormal prion protein, or due to a genetic variation in the prion protein gene (PRNP) (genetic CJD, Gerstmann-Straussler-Scheinker disease [GSS], fatal familial insomnia [FFI]). These diseases feature cognitive and motor dysfunction, although other presentations with various symptoms are possible. Imaging studies in sporadic CJD have primarily utilized DWI techniques to evaluate diffusion in gray matter and white matter structures. Sporadic CJD patients show increased diffusivity in the caudate, putamen, cerebellum, globus pallidus, and regions of the cerebral gray matter and white matter (\(^{-}\)Figs. 7A, –7B\(^{1,394-400}\)). The thalamus may also show abnormalities in some forms of sporadic CJD. Changes in the basal ganglia are associated with a faster disease progression. \(^{1,401}\) However, these alterations may disappear as the disease progresses in the presence of more severe atrophy. \(^{396,399,402}\) DWI and T2-weighted imaging studies in variant CJD show abnormalities in the pulvinar thalamus and sometimes in the dorsomedial thalamic nuclei (\(^{-}\)Figs. 7E-H\(^{1,394,395,403-405}\)).

---

**Fig. 7** Structural imaging changes in prion protein related diseases. (A) An axial T2-weighted magnetic resonance image (MRI) of a patient with sporadic Creutzfeldt-Jakob disease (CJD) shows a subtle increase in signal intensity in the left anterior putamen (arrow). (B) A diffusion weighted image (DWI) also shows a more apparent hyperintense signal in the bilateral caudate and left putamen. Patients with (C) genetic CJD and (D) Gerstmann-Straussler-Scheinker disease show notable cortical and cerebellar atrophy. (E) An axial fluid attenuated inversion recovery (FLAIR) image in a patient with variant CJD shows hyperintense signal in the dorsomedial thalamus and pulvinar bilaterally, creating a hockey stick pattern. (F) A similar pattern, although slightly less apparent, is seen on the DWI scan. (G) An axial T2-weighted MRI of a patient with variant CJD is of limited diagnostic value due to patient movement, while (H) the DWI scan shows prominent hyperintensity in the bilateral dorsomedial thalamus and pulvinar. (Adapted from Macfarlane et al\(^{395}\))
alterations are seen in the periaqueductal gray, caudate, and parieto-occipital white matter. Similar to sporadic CJD, these alterations may disappear as the disease progresses and atrophic changes expand. Studies utilizing MRS techniques have shown reduced NAA and increased mlNs in patients with variant CJD, likely reflecting ongoing neurodegeneration. SPECT studies have also shown cortical hypoperfusion in patients with variant CJD. iatrogenic CJD patients show increased diffusion on DWI and hyperintensities on T2-weighted scans in regions of the caudate head, putamen, cortical gray matter, and sometimes in the cerebellum and thalamus. Longitudinally, iatrogenic CJD patients show progressive atrophy associated with disease progression. MRS studies in iatrogenic CJD also demonstrated reduced NAA in the cerebellum. Genetic prion diseases also show changes in MRI and PET studies. Altered diffusion in the striatum, thalamus, and frontal and occipital cortices was observed in most genetic CJD patients. MRS studies have also shown increased levels of mlNs, but no change in NAA level in the cerebral cortex and basal ganglia in genetic CJD. Patients with GSS and some genetic CJD showed mixed results using structural MRI measures, with either no atrophy or generalized cerebral and hypoperfusion/metabolism. Future studies to further explore these rare diseases may provide additional insight into the pathologies underlying prion diseases, as well as monitoring of potential treatments.

Differential Diagnosis of Dementias

Differential diagnosis of degenerative conditions not associated with a known genetic variant or other disease state (i.e., HIV) can sometimes be difficult due to overlapping clinical symptoms. In diseases presenting without motor symptoms, such as late-onset AD, atypical AD, and some forms of FTD, structural MRI and PET studies can often be helpful in differentiating between diseases (Table 1). Specifically, patients with AD show significant degeneration in the MTL, as well as in posterior brain regions (i.e., parietal lobe), while patients with FTD show primarily frontal lobe and lateral temporal lobe degeneration, with relative sparing of most parietal lobe regions. Furthermore, PET studies with amyloid tracers will provide good delineation of AD/atypical AD and FTD syndromes, as AD patients will typically show significant amyloid deposition and FTD patients usually will not. Distinguishing between traditional late-onset AD and atypical forms of AD is most commonly based on clinical symptoms, as domains other than memory tend to be more affected in the atypical forms. However, structural MRI may also provide additional support for specific diagnoses, with PCA patients often showing greater parietal and occipital atrophy and logopenic aphasia showing more asymmetrical left posterior temporal and temporoparietal atrophy than seen in traditional AD. Patients with CAA and VaD will also present with more vascular abnormalities, including microbleeds/microhemorrhages, and white matter lesions than seen in more typical late-onset AD patients. Furthermore, the pattern of FDG PET hypometabolism in vascular dementia is less diffuse with patchy areas corresponding to hypoperfusion compared with the pattern observed in AD patients, and widespread amyloid deposition in pure vascular dementia without CAA is not commonly observed.

Distinguishing between diseases associated with motor symptoms in the absence or presence of cognitive symptoms can also be quite difficult. Frontotemporal dementia with motor neuron disease and FTD-ALS both show cognitive and motor symptoms and are associated atrophy and reduced perfusion/metabolism in frontal and temporal lobes. Differentiation of these two diseases is probably not well assisted by neuroimaging techniques currently. Parkinson’s disease dementia and DLB show greater basal ganglia and less MTL atrophy than seen in typical AD patients, as well as decreased dopaminergic neurotransmission in the striatum on PET or SPECT. Distinguishing PDD/DLB from FTD-MND/ALS using neuroimaging can potentially be difficult, although PDD/DLB patients tend to show more posterior cortical atrophy and hypoperfusion/metabolism, particularly in the parietal and occipital lobes, than seen in FTD-MND/ALS. Multiple sclerosis is characterized by the notable white matter lesions on T2-weighted and enhanced MRI scans, which are not as commonly seen in other degenerative disorders. Although MS is typically diagnosed at an earlier age, differentiation of MS and other demyelinating disorders and microvascular changes associated with aging or early VCI can be challenging in some cases. Finally, sporadic and variant prion diseases can be distinguished from most other dementias by the significant abnormalities seen in the thalamus relative to other areas of the brain, as well as history and other clinical features.

Conclusion

Imaging studies of neurodegenerative diseases and dementias are highly informative regarding structural, functional, and molecular brain changes underlying the observed clinical
symptoms. Often neuroimaging techniques can be helpful if not essential for differential diagnosis of various syndromes. Further studies with advanced MRI techniques and future PET tracers for proteinopathies beyond amyloid (i.e., tau, α-synuclein, and TDP-43) will likely provide even more information about pathology associated with the various degenerative and dementing syndromes. In addition, neuroimaging techniques may be useful in clinical trials of new therapeutics designed to treat these disabling and often refractory disorders for both monitoring disease-related changes or as endpoints to complement current clinical outcome measures.

Acknowledgments
This manuscript was supported by grants from the National Institute on Aging (NIA R01 AG19771, P30 AG10133).

References

Seminars in Neurology  Vol. 33  No. 4/2013

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.


Schuff N, Matsumoto S, Kmieciak J, et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer’s disease, measured...


176 Ebmeier KP, Filippini N, Heise V, Sexton CE. Other magnetic resonance imaging techniques. Int Psychogeriatr 2011;23 (Suppl 2):S55–S57


178 Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 2003;60(12):1904–1908


200 Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain 2003;126( Pt 11):2406–2418


